EYLEA Market Drug Insight and Market Forecast - 2032

EYLEA Market Drug Insight and Market Forecast − 2032

“EYLEA Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about EYLEA for Diabetic Retinopathy in the seven major markets. A detailed picture of the EYLEA for diabetic retinopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the EYLEA for diabetic retinopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EYLEA market forecast analysis for diabetic retinopathy in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in diabetic retinopathy.

Drug Summary

EYLEA (Aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a molecular protein weight of 97 kDa. It contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells. Eylea Injection is a sterile, clear, and colorless to pale yellow solution. Eylea is supplied as a preservative-free, sterile, aqueous solution for intravitreal injection in a single-dose, glass vial designed to deliver 0.05 mL (50 µL) of solution containing 2 mg of Eylea (40 mg/mL in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2).

Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF and thereby can inhibit the binding and activation of these cognate VEGF receptors.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the EYLEA description, mechanism of action, dosage and administration, research and development activities in diabetic retinopathy.

Elaborated details on EYLEA regulatory milestones and other development activities have been provided in this report.

The report also highlights the EYLEA research and development activities in diabetic retinopathy across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around EYLEA.

The report contains forecasted sales of for diabetic retinopathy till 2032.

Comprehensive coverage of the late-stage emerging therapies for diabetic retinopathy.

The report also features the SWOT analysis with analyst views for EYLEA in diabetic retinopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EYLEA Analytical Perspective by DelveInsight

In-depth EYLEA Market Assessment

This report provides a detailed market assessment of EYLEA for diabetic retinopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

EYLEA Clinical Assessment

The report provides the clinical trials information of EYLEA for diabetic retinopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for diabetic retinopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EYLEA dominance.

Other emerging products for diabetic retinopathy are expected to give tough market competition to EYLEA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EYLEA in diabetic retinopathy.

Our in-depth analysis of the forecasted sales data of EYLEA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EYLEA in diabetic retinopathy.

Key Questions

What is the product type, route of administration and mechanism of action of EYLEA?

What is the clinical trial status of the study related to EYLEA in diabetic retinopathy and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EYLEA development?

What are the key designations that have been granted to EYLEA for diabetic retinopathy?

What is the forecasted market scenario of EYLEA for diabetic retinopathy?

What are the forecasted sales of EYLEA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to EYLEA for diabetic retinopathy?

Which are the late-stage emerging therapies under development for the treatment of diabetic retinopathy?